Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Intubation/hospitalization 55% Improvement Relative Risk HCQ for COVID-19  Davido et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 132 patients in France Lower intubation/hosp. with HCQ (p=0.04) Davido et al., Int. J. Antimicrobial A.., Aug 2020 Favors HCQ Favors control

Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time

Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129
Aug 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU, HR=0.45, p=0.04. Adjusted for Charlson Comorbidity Index (including age), obesity, O2, lymphocyte count, and treatments. Mean delay from admission to treatment 0.7 days.
risk of intubation/hospitalization, 55.0% lower, HR 0.45, p = 0.04, treatment 12 of 80 (15.0%), control 13 of 40 (32.5%), NNT 5.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Davido et al., 2 Aug 2020, retrospective, France, peer-reviewed, 14 authors.
This PaperHCQAll
Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time
Benjamin Davido, Ghilas Boussaid, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, Christine Lawrence, Jean-Claude Alvarez, Pierre Moine, Véronique Perronne, Frédéric Barbot, Azzam Saleh-Mghir, Christian Perronne, Djillali Annane, Pierre De Truchis
Introduction: Interest of anti-infective agents in COVD-19 showed discrepant results. However, there is no evaluation about the impact in changes of practices on the prognosis over time. Methods: Single center, retrospective study, conducted from March 5 th to April 25 th 2020, in adults hospitalized in a medicine ward for a COVID-19. Patient characteristics were compared between 2 periods (before/after March 19 th ) considering French guidelines issued by learned societies. Aim of the study was to 3 evaluate how medical care impacted unfavorable outcome, namely admission in intensive care unit (ICU) and/or death. Results: One hundred thirty-two patients were admitted, mean age was 59.0 ± 16.3 years, mean CRP level was 84.0±71.1 mg/L, 46% had a lymphocyte count<1000/mm 3 . When prescribed, anti-infective agents were lopinavir-ritonavir (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) (n=52). Between the 2 periods we noted a significant decrease of ICU admission, from 43% to 12% (p<0.0001). Delays until transfer in ICU were similar between periods (p=0.86). Pulmonary CT-scan were significantly more performed (from 50% to 90%, p<0.0001), as oxygen-dependency (53% vs 80%, p=0.001) and prescription of AZI±HCQ (from 25% to 76%, p<0.0001) were greater over time. Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ (HR=0.45, 95%IC [0.21-0.97], p=0.04), especially among an identified category of individuals (lymphocyte≥1000/mm 3 or CRP≥100 mg/L). Conclusion: The present study revealed a significant decrease of admission in ICU over time probably related to multiple factors, including a better indication of pulmonary CT-scan, of oxygen therapy, and a suitable prescription of anti-infective agents.
Declarations Funding: The authors have no financial relationships relevant to this article to disclose. Competing Interests: BD has received consulting fees or travel grants from ViiV Healthcare and Gilead Sc. PdT has received consulting fees or travel grants from ViiV Healthcare, M.S.D and Gilead Sc. The remaining authors have no specific conflict of interest. Ethical Approval: Not required
Ambrosi, None, MD
Amthor, None, MD
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.06.099
Barbarin, None
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Preliminary Report, N Engl J Med, doi:10.1056/nejmoa2007764
Berradja, None, MD
Borba, Val, Sampaio, Alexandre, Melo et al., Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.8857
Bounab, None, MD
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Carlier, None, MD
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis
Chentouh, None, MD
Chetrit, None, MD
Chkron, Céline Karabulut
Clair, None, MD
Coester, None, MD
Davido, Md, None, MS
Defouchecour, None, MD
Denys, Md, None, PhD
Dh, Azithromycin, a 15-membered Macrolide Antibiotic, Inhibits Influenza A(H1N1)pdm09 Virus Infection by Interfering With Virus Internalization Process, J Antibiot, doi:10.1038/S41429-019-0204-X
Diffre, None, MD
Djebrani, Pharmd, Emmanuelli, None
Dosne, None, MD
Edjlali, Md, None, PhD
El, None, MD
Farcy-Afif, None, PharmD
Fayssoil, None, MD
Felter, None, MD
Foch, None
Friedman, None, MD
Gault, Md, None, PhD
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101663
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Girardot, None, MD
Group, Assistance Publique-Hôpitaux de Paris' response to the COVID-19 pandemic, Lancet, doi:10.1016/S0140-6736(20)31210-1
Guichard, None, MD
Guillon, Omar, Md, Laboratory of Physiology Frédéric Lofaso, PhD
Hamon Pietrin, Md, None, PhD
Heming, Md, None, PhD
Herrmann, None, PharmD
Hôpital, Poincaré, Aphp, None
Jabbour, None, PharmD
Joussain, Md, None, PhD
Jouvenet, Santé, Clinique de la Muette
Kagane, None, MD
Khiter, None, MD
Kirchner, None
Kumar, Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life, doi:10.1093/jac/dkr090
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/J.TMAID.2020.101791
Lahjomri, None, MD
Lamy, None
Landowski, None, MD
Lanore, None
Lansaman, None, MD
Lawrence, None, PharmD
Lb, Tw, Dt, Am, Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial, JAMA, doi:10.1001/JAMA.2015.13896
Le Liepvre, Md ; Leotard, None, MS
Le, None
Lebidois, None, PharmD
Lemoine, None
Levy, Md, None, MS
Louis Gaillard, Md, None, PhD
Lyse, None, MD
Mahévas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844
Malot, None, MD
Mantaise, Mantes-La-Jolie
Martinez, Md, None, PhD
Maxime, Md, None
Mekki, Md, None, MS
Meuleye, None, MD
Michelon, Pharmd, None, MSc
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Moine, Md, None, PhD
Mompoint, None, MD
Nguyen, Thang, Department of Microbiology and Innovative Biomarkers Platform Coralie Favier
Niel, None, MD
Noussair, None, MD
Orlikowski, Md, None, PhD
Paquereau, None, MD
Parent, Md, And the nonmedical staff of the Department Department of Radiology Amine Ammar
Perronne, Md, None, PhD
Perronne, None, MD
Pierre De Truchis, Md, None, MS
Prigent, Md, None, MD, PhD
Rech, Md, None
Reysz, None, MD
Roquencourt, None, MD
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Rottman, Md, None, PhD
Roux, None, PharmD
Russell, Millar, Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, doi:10.1016/S0140-6736(20)30317-2
Safa, None, MD
Saffroy, None
Santi, Md, Pharmacy Frédérique Bouchand, PharmD
Schitter, None, MD
Stanislas Grassin, None, MCUPH
Tan, Wang, Zhang, Ding, Huang et al., Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, Signal Transduct Target Ther, doi:10.1038/s41392-020-0148-4
Thevenot, Department of Intensive Care Interns Baptiste Abbar
Thiry, Md, Department of Radiology Interns Margot Armani (1) Olivier de Barry
Tn, Hematological Findings and Complications of COVID-19, Am J Hematol, doi:10.1002/AJH.25829
Tocqueville, None
Touret, Gilles, Barral, Nougairède, Decroly et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, BioRxiv, doi:10.1101/2020.04.03.023846
Trabelsi, Md, Pediatric Critical Care Unit Helge Amthor, MD, PhD
Ulrich, Pillat, CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement, doi:10.1007/s12015-020-09976-7
Vibert, Department of Infectious Diseases Pascal Crenn, PhD
Villart, None, PharmD
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Welti, Md, And the nonmedical staff of the Department Department of Laboratory Medicine and Pharmacology Jean Claude Alvarez, PhD
Zhao, Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105982
Zhou, Department of Forensic Medicine Geoffroy Lorin de La Grandmaison MD, PhD
Zini, Department of Anesthesia, Perioperative Care, and Pain Marie Boutros
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop